Role of neutrophil-to-lymphocyte ratio in prediction of Gleason score upgrading and disease upstaging in low-risk prostate cancer patients eligible for active surveillance

Canadian Urological Association Journal

Volumn 10, Issue 11-12, 2016, Pages E383-E387

  Gokce, Mehmet Ilker ^a   Tangal, Semih ^b   Hamidi, Nurullah ^a   Suer, Evren ^a   Ibis, Muhammed Arif ^a   Beduk, Yasar ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b UFUK UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CLINICAL EVALUATION; COST EFFECTIVENESS ANALYSIS; DISEASE SURVEILLANCE; GLEASON SCORE; HUMAN; LOW RISK PATIENT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL LYMPHOCYTE RATIO; PREDICTION; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL TIME;

EID: 84995378502     PISSN: 19116470     EISSN: 19201214     Source Type: Journal    
DOI: 10.5489/cuaj.3550     Document Type: Article

References (18)

1. Prostate cancer estimated incidence, mortality, and prevalence worldwide in 2012. Available at http:// globocan.iarc.fr/old/FactSheets/cancers/prostate-new.asp. Accessed October 4, 2016.
2. Cooperberg MR, Broering JM, Kantoff PW, et al. Contemporary trends in low-risk prostate cancer: Risk assessment and treatment. J Urol 2007;178:S14. http://dx.doi.org/10.1016/j.juro.2007.03.135
3. National Comprehensive Cancer Network. Available at http://www.nccn.org/professionals/physician-gls/pdf/prostate.pdf. Accessed October 4, 2016.
4. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate cancer survivors. N Engl J Med 2008;358:1250-61. http://dx.doi.org/10.1056/NEJMoa074311
5. Alemozaffar M, Regan MM, Cooperberg MR, et al. Prediction of erectile function following treatment for prostate cancer. JAMA 2011;306:1205-14. http://dx.doi.org/10.1001/jama.2011.1333
6. Cooperberg M, Carroll PR, Klotz L. Active surveillance for prostate cancer: Progress and promise. J Clin Oncol 2011;29:3669-76. http://dx.doi.org/10.1200/JCO.2011.34.9738
7. Sundi D, Ross AE, Humphreys EB, et al. African-American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: Should active surveillance still be an option for them? J Clin Oncol 2013;31:2991-7. http://dx.doi.org/10.1200/JCO.2012.47.0302
8. Schreiber D, Chhabra A, Rineer J, et al. A population-based study of men with low-volume, low-risk prostate cancer: Does African-American race predict for more aggressive disease? Clin Genitourin Cancer 2015;13:e259-64. http://dx.doi.org/10.1016/j.clgc.2015.02.006
9. Behbahani TE, Ellinger J, Caratozzolo DG, et al. Pathological outcomes of men eligible for active surveillance after undergoing radical prostatectomy: Are results predictable? Clin Genitourin Cancer 2012;10:32-6. http://dx.doi.org/10.1016/j.clgc.2011.09.004
10. Templeton AJ, McNamara MG, Seruga B, et al. Prognostic role of neutrophilto-lymphocyte ratio in solid tumours: A systematic review and meta-analysis. J Natl Cancer Inst 2014;106:dju124. http://dx.doi. org/10.1093/jnci/dju124
11. Ozcan C, Telli O, Ozturk E et al. The prognostic significance of preoperative leukocytosis and neutrophilto-lymphocyte ratio in patients who underwent radical cystectomy for bladder cancer. Can Urol Assoc J 2015;9:E789-94. http://dx.doi.org/10.5489/cuaj.3061
12. van Soest RJ, Templeton AJ, Vera-Badillo FE, et al. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: Data from two randomized phase 3 trials. Ann Oncol 2015;26:743-9. http://dx.doi.org/10.1093/annonc/mdu569
13. Kwon YS, Han CS, Yu JW, et al. Neutrophil and lymphocyte counts as clinical markers for stratifying low-risk prostate cancer. Clin Genitourin Cancer 2016;14:e1-8. http://dx.doi.org/10.1016/j.clgc.2015.07.018
14. Gokce MI, Hamidi N, Suer E, et al. Evaluation of neutrophil-to-lymphocyte ratio prior to prostate biopsy to predict biopsy histology: Results of 1836 patients. Can Urol Assoc J 2015;9:E761-5. http://dx.doi. org/10.5489/cuaj.3091
15. Cary KC, Cooperberg MR. Biomarkers in prostate cancer surveillance and screening: Past, present, and future. Ther Adv Urol 2013;5:318-29. http://dx.doi.org/10.1177/1756287213495915
16. Catalona WJ, Partin AW, Sanda MG, et al. A multicentre study of [-2]pro-prostate-specific antigen combined with prostate-specific antigen and free prostate-specific antigen 16 for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate-specific antigen range. J Urol 2011;185:1650-5. http://dx.doi. org/10.1016/j.juro.2010.12.032
17. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: Prediction, detection, and monitoring. Nat Rev Cancer 2008;8:268-78. http://dx.doi.org/10.1038/nrc2351
18. Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology 2007;121:1-14. http://dx.doi.org/10.1111/j.1365-2567.2007.02587.x